MCID: ESP024
MIFTS: 62

Esophagitis

Categories: Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Esophagitis

MalaCards integrated aliases for Esophagitis:

Name: Esophagitis 12 54 43 15 71
Acute Esophagitis 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11963
ICD9CM 34 530.1 530.10
MeSH 43 D004941
NCIt 49 C9224
SNOMED-CT 67 16761005
ICD10 32 K20 K20.9
UMLS 71 C0014868 C0149882

Summaries for Esophagitis

MalaCards based summary : Esophagitis, also known as acute esophagitis, is related to esophageal basaloid squamous cell carcinoma and esophageal cancer, and has symptoms including pain in esophagus (finding) An important gene associated with Esophagitis is CCL26 (C-C Motif Chemokine Ligand 26), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Famotidine and Trimebutine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Esophagitis (British spelling oesophagitis) (Greek ????????? "gullet" and -itis "inflammation") is a... more...

Related Diseases for Esophagitis

Diseases in the Esophagitis family:

Bacterial Esophagitis Viral Esophagitis

Diseases related to Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2045)
# Related Disease Score Top Affiliating Genes
1 esophageal basaloid squamous cell carcinoma 34.3 TP53 EGFR
2 esophageal cancer 33.9 TP53 TNF STAT3 PTGS2 POSTN IL6
3 barrett esophagus 33.9 TP53 PTGS2 IL6 GAST EGFR ASCC1
4 adenocarcinoma 33.3 TP53 STAT3 PTGS2 EGFR ASCC1
5 peptic esophagitis 33.3 PTGS2 IL6 IL1B HRH2 GAST CYP2C19
6 esophagus adenocarcinoma 33.0 TP53 PTGS2 EGFR
7 esophagus melanoma 32.8 IL1B CXCL8
8 fatty liver disease 32.5 TNF IL6 IL1B CXCL8
9 varicose veins 32.0 TNF IL6 CXCL8
10 kaposi sarcoma 32.0 TP53 STAT3 IL6 CXCL8 CCR3
11 systemic scleroderma 31.9 TNF IL6 IL4 HRH2 GAST
12 esophagitis, eosinophilic, 1 31.9 TSLP POSTN IL5 IL4 IL13 CCR3
13 hernia, hiatus 31.7 HRH2 GAST CYP2C19
14 eosinophilic gastritis 31.7 IL5 IL13 CCR3 CCL26 CCL11
15 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.5 PTGS2 HRH2 GAST
16 papilloma 31.3 TP53 PTGS2 IL4 EGFR
17 acquired immunodeficiency syndrome 31.3 TP53 TNF IL6 IL1B
18 small cell carcinoma 31.2 TP53 GAST EGFR
19 helicobacter pylori infection 31.1 IL1B GAST EGFR CYP2C19 CXCL8
20 cytokine deficiency 31.1 IL5 IL13
21 oral cancer 31.0 TP53 PTGS2 EGFR
22 pericarditis 31.0 TNF IL6 IL1B CXCL8
23 hepatic encephalopathy 31.0 TNF STAT3 IL6
24 ige responsiveness, atopic 31.0 IL5 IL4 IL13
25 lung abscess 31.0 TNF STAT3 IL6
26 candidiasis 30.9 TNF STAT3 IL6 IL4 IL1B CXCL8
27 exanthem 30.9 TNF IL6 EGFR CXCL8
28 alcoholic liver cirrhosis 30.9 TNF IL6 IL1B CXCL8
29 crohn's colitis 30.9 TNF IL1B CXCL8
30 active peptic ulcer disease 30.9 PTGS2 HRH2 CYP2C19
31 ileus 30.8 TNF IL6 IL1B
32 sleep apnea 30.8 TNF IL6 IL1B CXCL8
33 graft-versus-host disease 30.8 TNF IL6 IL1B
34 lichen planus 30.7 TP53 TNF IL6 IL4 CXCL8
35 laryngitis 30.7 TNF IL6 IL1B HRH2
36 pharyngitis 30.7 TNF PTGS2 IL6 IL1B CXCL8
37 colorectal adenocarcinoma 30.7 TP53 STAT3 PTGS2 EGFR
38 lymphadenitis 30.7 TNF STAT3 IL1B CXCL8
39 bronchopneumonia 30.7 TNF IL6 CXCL8
40 spinal cord injury 30.6 TNF IL6 CXCL8
41 gastrointestinal carcinoma 30.6 TP53 IL6 GAST
42 myositis 30.6 TNF IL6 IL1B CXCL8
43 food allergy 30.6 TNF IL5 IL4 IL13 CXCL8
44 cholangitis 30.6 TP53 TNF IL6 CXCL8
45 chagas disease 30.6 TNF IL6 IL4 IL1B CXCL8
46 bacterial infectious disease 30.6 TNF IL6 IL1B CXCL8
47 cytomegalovirus infection 30.6 TNF IL6 IL1B CXCL8
48 crohn's disease 30.6 TNF STAT3 IL6 IL4 IL1B CXCL8
49 apnea, obstructive sleep 30.5 TNF IL6 CXCL8
50 pulmonary edema 30.5 TNF IL1B IL13 CXCL8

Comorbidity relations with Esophagitis via Phenotypic Disease Network (PDN): (show top 50) (show all 109)


Active Peptic Ulcer Disease Acute Cystitis
Acute Maxillary Sinusitis Acute Pancreatitis
Alcoholic Gastritis Allergic Rhinitis
Angina Pectoris Anxiety
Aortic Valve Disease 1 Atrophic Gastritis
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Maxillary Sinusitis
Chronic Pulmonary Heart Disease Chronic Rhinitis
Chylomicron Retention Disease Conn's Syndrome
Conversion Disorder Cystitis
Deficiency Anemia Dependent Personality Disorder
Dermatomycosis Diabetic Polyneuropathy
Duodenitis Dyskinesia of Esophagus
Dysthymic Disorder Esophageal Cancer
Esophageal Candidiasis Esophageal Disease
Esophageal Varix First-Degree Atrioventricular Block
Gallbladder Disease Gastrin Secretion Abnormality
Gastritis, Familial Giant Hypertrophic Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hepatitis
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hypertension, Essential Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome

Graphical network of the top 20 diseases related to Esophagitis:



Diseases related to Esophagitis

Symptoms & Phenotypes for Esophagitis

UMLS symptoms related to Esophagitis:


pain in esophagus (finding)

MGI Mouse Phenotypes related to Esophagitis:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 CCR3 EGFR GAST HRH2 IL13 IL1B
2 hematopoietic system MP:0005397 10.32 CCL11 CCR3 EGFR IL13 IL1B IL4
3 immune system MP:0005387 10.31 CCL11 CCR3 EGFR GAST IL13 IL1B
4 digestive/alimentary MP:0005381 10.29 EGFR GAST HRH2 IL13 IL4 IL5
5 endocrine/exocrine gland MP:0005379 10.24 EGFR GAST HRH2 IL13 IL4 IL6
6 integument MP:0010771 10.1 EGFR IL13 IL1B IL4 IL6 PTGS2
7 adipose tissue MP:0005375 10.08 EGFR IL6 POSTN PTGS2 STAT3 TNF
8 craniofacial MP:0005382 10.07 EGFR IL1B IL4 POSTN STAT3 TNF
9 liver/biliary system MP:0005370 9.97 EGFR IL4 IL5 IL6 PTGS2 STAT3
10 neoplasm MP:0002006 9.96 EGFR GAST IL1B IL5 IL6 POSTN
11 muscle MP:0005369 9.92 EGFR IL13 IL6 POSTN PTGS2 STAT3
12 reproductive system MP:0005389 9.85 EGFR IL13 IL4 IL5 IL6 POSTN
13 respiratory system MP:0005388 9.73 CCL11 CCR3 EGFR IL13 IL4 IL5
14 skeleton MP:0005390 9.32 EGFR IL13 IL1B IL4 IL6 POSTN

Drugs & Therapeutics for Esophagitis

Drugs for Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 335)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Famotidine Approved Phase 4 76824-35-6 3325
2
Trimebutine Approved Phase 4 39133-31-8
3
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Ondansetron Approved Phase 4 99614-02-5 4595
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
leucovorin Approved Phase 4 58-05-9 6006 143
9
Pemetrexed Approved, Investigational Phase 4 150399-23-8, 137281-23-3 446556 60843
10
Calcium polycarbophil Approved Phase 4 126040-58-2
11
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Zinc Approved, Investigational Phase 4 7440-66-6 32051
14
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
15
Citalopram Approved Phase 4 59729-33-8 2771
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
18
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
19
Ramosetron Investigational Phase 4 132036-88-5
20 Rebamipide Investigational Phase 4 90098-04-7
21 Mosapride Investigational Phase 4 112885-41-3
22
Polaprezinc Experimental Phase 4 107667-60-7
23 Indobufen Investigational Phase 4 63610-08-2
24 Neurotransmitter Agents Phase 4
25 glucocorticoids Phase 4
26 Fibrinolytic Agents Phase 4
27 Antipruritics Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 BB 1101 Phase 4
30 Antirheumatic Agents Phase 4
31 Psychotropic Drugs Phase 4
32 Antipsychotic Agents Phase 4
33 Tranquilizing Agents Phase 4
34 Anti-Anxiety Agents Phase 4
35 Central Nervous System Depressants Phase 4
36 Serotonin Antagonists Phase 4
37 Antipyretics Phase 4
38 Cyclooxygenase Inhibitors Phase 4
39 HIV Protease Inhibitors Phase 4
40
protease inhibitors Phase 4
41 Emetics Phase 4
42 Antineoplastic Agents, Hormonal Phase 4
43 Soy Bean Phase 4
44 Cromolyn Sodium Phase 4
45 Omeprazole, sodium bicarbonate drug combination Phase 4
46 Serotonin Receptor Agonists Phase 4
47 Olive Phase 4
48 Folic Acid Antagonists Phase 4
49 Vitamin B Complex Phase 4
50 Vitamin B9 Phase 4

Interventional clinical trials:

(show top 50) (show all 647)
# Name Status NCT ID Phase Drugs
1 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
2 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
5 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
6 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
7 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
8 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
9 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis. Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
10 An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
11 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
12 The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis Completed NCT01874535 Phase 4 Esomeprazole 40 mg
13 A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
14 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
15 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE) Completed NCT03116841 Phase 4 Vonoprazan
16 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
17 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed. Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
18 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
19 Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
20 Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
21 Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
22 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment Completed NCT00242736 Phase 4 Esomeprazole
23 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
24 A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
25 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study Completed NCT01135368 Phase 4 Lansoprazole
26 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
27 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
28 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
29 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
30 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
31 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
33 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
34 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
35 Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing Completed NCT00307944 Phase 4 Pantoprazole
36 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
37 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
38 Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD) Completed NCT00574925 Phase 4 Esomeprazole
39 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4 Ilaprazole
40 An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Completed NCT03079050 Phase 4 Dexlansoprazole 60 MG
41 PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD Completed NCT00261339 Phase 4 Pantoprazole
42 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
43 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
44 Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus. Completed NCT00476398 Phase 4
45 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
46 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
47 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
48 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
49 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
50 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4

Search NIH Clinical Center for Esophagitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
lansoprazole
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
pantoprazole
Pantoprazole sodium
Sucralfate

Cochrane evidence based reviews: esophagitis

Genetic Tests for Esophagitis

Anatomical Context for Esophagitis

MalaCards organs/tissues related to Esophagitis:

40
Lung, Testes, Bone, Heart, Liver, Breast, Colon

Publications for Esophagitis

Articles related to Esophagitis:

(show top 50) (show all 12726)
# Title Authors PMID Year
1
Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. 54 61
20208004 2010
2
Regulation of CDX2 expression in esophageal adenocarcinoma. 54 61
19415720 2009
3
Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. 54 61
18844613 2008
4
[Eosinophilic esophagitis : a cause of dysphagia]. 54 61
18214405 2008
5
Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease. 54 61
17900656 2007
6
IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. 54 61
18073124 2007
7
Alterations in manganese superoxide dismutase expression in the progression from reflux esophagitis to esophageal adenocarcinoma. 54 61
17473952 2007
8
Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. 54 61
17059896 2006
9
CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. 54 61
16868800 2006
10
Roles of epidermal growth factor and Na+/H+ exchanger-1 in esophageal epithelial defense against acid-induced injury. 54 61
16306134 2006
11
What is the best way to manage GERD symptoms in the elderly? 54 61
16510061 2006
12
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. 54 61
16453027 2006
13
Eosinophilic esophagitis. 54 61
16282772 2005
14
Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease. 54 61
16302983 2005
15
Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. 54 61
15884106 2005
16
The relationship between the esophageal tissue content of neurotensin and the presence or absence of esophageal inflammation. 54 61
14992433 2004
17
Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. 54 61
14724818 2003
18
Regulation of Na/H exchanger-1 in gastroesophageal reflux disease: possible interaction of histamine receptor. 54 61
14561010 2003
19
Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. 54 61
12560917 2003
20
Infiltrating eosinophils and eotaxin: their association with idiopathic eosinophilic esophagitis. 54 61
12392390 2002
21
Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation. 54 61
11474496 2001
22
The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. 54 61
11403754 2001
23
Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. 54 61
11121210 2001
24
Plasmid/liposome transfer of the human manganese superoxide dismutase transgene prevents ionizing irradiation-induced apoptosis in human esophagus organ explant culture. 54 61
10900424 2000
25
Gastroesophageal reflux disease: pathophysiology and pharmacology overview. 54 61
10826019 2000
26
Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. 54 61
10492161 1999
27
Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance. 54 61
9165690 1996
28
Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy. 61
30994520 2020
29
Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies. 61
31784801 2020
30
Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. 61
31714592 2020
31
Eosinophilic esophagitis and other eosinophilic disorders of the gastrointestinal tract. 61
32017217 2020
32
Integration of a clinical scoring system in the management of eosinophilic esophagitis. 61
31421277 2020
33
Efficacy of Epicutaneous Immunotherapy in Children With Milk-Induced Eosinophilic Esophagitis. 61
31100455 2020
34
SERPINB12 as a possible marker of steroid dependency in children with eosinophilic esophagitis: A pilot study. 61
31653522 2020
35
The Role of MIF on Eosinophil Biology and Eosinophilic Inflammation. 61
30680604 2020
36
Reply to Dr Khan. 61
32012338 2020
37
Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis. 61
32036755 2020
38
Mast Cell Infiltration Is Associated With Persistent Symptoms and Endoscopic Abnormalities Despite Resolution of Eosinophilia in Pediatric Eosinophilic Esophagitis. 61
31913192 2020
39
Oral desensitization in IgE-mediated food allergy: Effectiveness and safety. 61
32017216 2020
40
Association between visceral abdominal obesity and long-segment Barrett's esophagus in a Japanese population. 61
31667587 2020
41
Lymphocyte-predominant Esophagitis: A Distinct and Likely Immune-mediated Disorder Encompassing Lymphocytic and Lichenoid Esophagitis. 61
31651525 2020
42
The endoscopic pressure study integrated system (EPSIS) reflects gastroesophageal junction competence in patients with erosive esophagitis and Barrett´s esophagus. 61
32012362 2020
43
A Holistic Approach to Diagnosing and Treating Dysphagia. 61
32026277 2020
44
Predictive Factors of Gastroesophageal Reflux Disease in Bariatric Surgery: a Controlled Trial Comparing Sleeve Gastrectomy with Gastric Bypass. 61
32030616 2020
45
Alport-leiomyomatosis syndrome requiring subtotal esophagectomy for refractory gastroesophageal reflux disease after childhood partial esophagogastrectomy: a case report. 61
31758390 2020
46
Individualized prediction of late-onset dysphagia in head and neck cancer survivors. 61
32031294 2020
47
Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas. 61
31655197 2020
48
Mixed adenoneuroendocrine carcinoma of the liver: A rare case report. 61
31929886 2020
49
Functional Outcomes of Delta-Shaped Anastomosis After Laparoscopic Distal Gastrectomy. 61
32026335 2020
50
Laparoscopic Single Anastomosis Sleeve Ileal (SASI) Bypass for Patients With Morbid Obesity: Technical Description and Short-term Outcomes. 61
32032329 2020

Variations for Esophagitis

Expression for Esophagitis

Search GEO for disease gene expression data for Esophagitis.

Pathways for Esophagitis

Pathways related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TP53 TNF STAT3 PTGS2 IL6 IL5
2
Show member pathways
13.88 TP53 TNF STAT3 PTGS2 IL6 IL5
3
Show member pathways
13.67 TSLP TP53 TNF STAT3 PTGS2 IL6
4
Show member pathways
13.63 TP53 TNF STAT3 IL6 IL5 IL4
5
Show member pathways
13.45 TP53 TNF STAT3 IL6 IL5 IL4
6
Show member pathways
13.41 TP53 TNF STAT3 PTGS2 IL6 IL5
7
Show member pathways
13.39 TNF IL6 IL5 IL4 IL1B IL13
8
Show member pathways
13.21 TP53 TNF STAT3 IL6 IL1B EGFR
9
Show member pathways
13.06 TP53 TNF PTGS2 IL6 IL4 EGFR
10
Show member pathways
13.05 TP53 TNF STAT3 PTGS2 IL6 IL1B
11
Show member pathways
12.98 TNF IL6 IL5 IL4 IL1B IL13
12 12.95 TP53 STAT3 PTGS2 IL6 IL5 IL4
13
Show member pathways
12.91 TP53 TNF STAT3 IL6 IL1B CXCL8
14
Show member pathways
12.74 TP53 TNF STAT3 IL1B EGFR
15
Show member pathways
12.74 TNF STAT3 IL6 IL5 IL4 IL1B
16
Show member pathways
12.74 TNF STAT3 IL6 IL5 IL4 IL1B
17
Show member pathways
12.71 TP53 TNF STAT3 IL6 IL1B EGFR
18
Show member pathways
12.67 TNF PTGS2 IL5 IL4 IL13
19 12.65 TNF STAT3 PTGS2 IL4 IL1B
20
Show member pathways
12.54 TP53 IL5 IL1B IL13 EGFR
21 12.48 TP53 TNF IL1B EGFR CXCL8
22
Show member pathways
12.48 TNF IL6 CXCL8 CCR3 CCL26 CCL11
23
Show member pathways
12.47 TP53 TNF PTGS2 IL6 IL4 IL1B
24
Show member pathways
12.47 TSLP STAT3 IL6 IL5 IL4 IL13
25
Show member pathways
12.46 TP53 TNF PTGS2 IL6 IL1B CXCL8
26
Show member pathways
12.4 CXCL8 CCR3 CCL26 CCL11
27
Show member pathways
12.38 TNF STAT3 PTGS2 IL4 IL1B
28
Show member pathways
12.37 TNF PTGS2 IL6 IL1B EGFR CXCL8
29 12.36 TP53 TNF STAT3 EGFR
30 12.36 TNF IL6 IL1B CXCL8
31 12.34 TP53 TNF STAT3 PTGS2 IL6 EGFR
32
Show member pathways
12.34 TP53 TNF IL6 IL5 IL4 IL1B
33
Show member pathways
12.33 TNF IL6 IL4 IL1B CXCL8 CCL11
34 12.31 TNF IL6 IL1B CXCL8
35 12.31 TNF IL6 IL1B IL13 CXCL8
36
Show member pathways
12.29 TNF PTGS2 IL6 IL1B
37
Show member pathways
12.29 TNF STAT3 PTGS2 IL6 IL5 IL4
38
Show member pathways
12.18 TNF IL6 IL4 IL1B IL13
39
Show member pathways
12.18 TP53 STAT3 IL5 IL1B IL13 EGFR
40
Show member pathways
12.15 TNF STAT3 IL6 IL1B
41 12.14 TNF IL6 IL5 IL4 CCR3
42 12.11 TNF IL6 IL1B CXCL8
43 12.09 TP53 TNF PTGS2 IL6 IL4 IL1B
44 12.07 TNF PTGS2 IL6 IL1B
45 12.07 TNF STAT3 IL6 IL1B CXCL8
46 12.06 TNF IL6 IL5 IL4 IL1B
47 12.05 TP53 IL6 IL1B CXCL8
48 12.03 TNF PTGS2 IL1B CXCL8
49 12.02 TNF IL6 IL1B CXCL8
50 11.98 TNF IL6 IL1B CXCL8

GO Terms for Esophagitis

Cellular components related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TSLP TNF POSTN IL6 IL5 IL4
2 extracellular space GO:0005615 9.44 TSLP TNF POSTN IL6 IL5 IL4

Biological processes related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 TP53 TNF STAT3 IL6 IL4 IL1B
2 signal transduction GO:0007165 10.13 TSLP STAT3 IL6 IL5 IL4 IL1B
3 negative regulation of cell proliferation GO:0008285 10.1 TP53 STAT3 PTGS2 IL6 IL1B CXCL8
4 negative regulation of apoptotic process GO:0043066 10.08 TSLP TP53 STAT3 PTGS2 IL6 IL4
5 positive regulation of cell proliferation GO:0008284 10.07 TSLP STAT3 PTGS2 IL6 IL5 IL1B
6 positive regulation of transcription, DNA-templated GO:0045893 10.06 TP53 TNF STAT3 IL6 IL5 IL4
7 positive regulation of cell migration GO:0030335 10.03 STAT3 IL1B EGFR CCL26 CCL11
8 positive regulation of gene expression GO:0010628 10.02 TP53 TNF STAT3 IL6 IL4 IL1B
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 TNF EGFR CCL26 CCL11
10 cellular response to lipopolysaccharide GO:0071222 10 TNF IL6 IL1B CXCL8
11 chemotaxis GO:0006935 9.99 CXCL8 CCR3 CCL26 CCL11
12 regulation of cell proliferation GO:0042127 9.99 TP53 TNF STAT3 PTGS2 EGFR
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF STAT3 IL6 IL1B
14 cellular response to tumor necrosis factor GO:0071356 9.97 POSTN CXCL8 CCL26 CCL11
15 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNF IL6 IL5 IL1B
16 response to estradiol GO:0032355 9.94 STAT3 PTGS2 POSTN EGFR
17 positive regulation of inflammatory response GO:0050729 9.92 TSLP TNF IL1B EGFR
18 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 TNF PTGS2 IL6 EGFR
19 neutrophil chemotaxis GO:0030593 9.91 IL1B CXCL8 CCL26 CCL11
20 positive regulation of endothelial cell proliferation GO:0001938 9.9 CCR3 CCL26 CCL11
21 cellular response to mechanical stimulus GO:0071260 9.9 PTGS2 IL1B IL13 EGFR
22 immune response GO:0006955 9.9 TNF IL6 IL5 IL4 IL1B IL13
23 cellular response to drug GO:0035690 9.89 TP53 IL1B EGFR
24 cellular response to organic cyclic compound GO:0071407 9.89 TNF STAT3 IL1B
25 positive regulation of angiogenesis GO:0045766 9.89 STAT3 IL1B CXCL8 CCR3 CCL11
26 response to glucocorticoid GO:0051384 9.88 TNF PTGS2 IL6
27 positive regulation of T cell proliferation GO:0042102 9.88 IL6 IL4 IL1B
28 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF IL1B EGFR
29 chemokine-mediated signaling pathway GO:0070098 9.87 CXCL8 CCR3 CCL26 CCL11
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF PTGS2 IL1B
31 monocyte chemotaxis GO:0002548 9.86 IL6 CCL26 CCL11
32 positive regulation of B cell proliferation GO:0030890 9.85 IL5 IL4 IL13
33 positive regulation of interleukin-6 production GO:0032755 9.85 TSLP TNF IL6 IL1B
34 negative regulation of mitotic cell cycle GO:0045930 9.84 TP53 TNF EGFR
35 positive regulation of vasoconstriction GO:0045907 9.83 PTGS2 HRH2 EGFR
36 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 IL5
37 positive regulation of vascular endothelial growth factor production GO:0010575 9.82 PTGS2 IL6 IL1B
38 positive regulation of chemokine production GO:0032722 9.78 TSLP TNF IL6
39 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 TNF PTGS2 IL6 IL13 EGFR
40 positive regulation of glial cell proliferation GO:0060252 9.76 TNF IL6 IL1B
41 astrocyte activation GO:0048143 9.75 TNF IL1B EGFR
42 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.73 TP53 EGFR
43 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.73 TNF STAT3 IL1B
44 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TSLP TNF STAT3 IL6 IL4 IL13
45 regulation of neuroinflammatory response GO:0150077 9.72 PTGS2 IL6
46 response to salt stress GO:0009651 9.72 TP53 TNF
47 positive regulation of interleukin-13 production GO:0032736 9.72 TSLP IL4
48 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
49 negative regulation of neurogenesis GO:0050768 9.71 TNF IL6 IL1B CCL11
50 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B

Molecular functions related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.33 CXCL8 CCL26 CCL11
2 cytokine activity GO:0005125 9.32 TSLP TNF IL6 IL5 IL4 IL1B
3 CCR3 chemokine receptor binding GO:0031728 8.96 CCL26 CCL11

Sources for Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....